The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) by Jung, Susanne et al.
RESEARCH Open Access
The impact of hyperbaric oxygen therapy on
serological values of vascular endothelial
growth factor (VEGF) and basic fibroblast
growth factor (bFGF)
Susanne Jung
1, Kai Wermker
1, Harald Poetschik
2, Thomas Ziebura
3, Johannes Kleinheinz
1*
Abstract
Background: Hyperbaric oxygen (HBO) therapy is an effective adjunct treatment for ischemic disorders such as
chronic infection or chronic wounds. It combines hyperoxic effects with the stimulating potential of post-
therapeutic reactive hypoxia. As its crucial effects, stimulation of fibroblast growth, induction of collagen synthesis
and the initiation of angiogenesis are discussed. Angiogenesis is a multistage process resulting in the growth of
blood vessels. It includes degradation of extracellular matrix, proliferation and migration of different cell
populations and finally formation of new vessel structures. This complex chain of procedures is orchestrated by
different cytokines and growth factors. Crucial mediators of angiogenesis are basic fibroblast growth factor (bFGF)
and vascular endothelial growth factor (VEGF); their in-vivo function is still not fully understood.
Methods: Forty-three patients suffering from sudden sensorineural hearing loss or tinnitus were treated with HBO.
The therapy included 10 sessions of 90 minutes each, one session a day. Serological levels of bFGF and VEGF were
assessed by enzyme-linked immunosorbent assays performed according to the manufacturer’s instructions on day
1, 2, 5 and 10 of HBO therapy and were compared to mean values of the control group, related to the patient’s
age and sex, and their development observed over the ten days of HBO.
Results: There was no sex- or age dependency of bFGF observed in the present study, whereas under HBO our
results showed a significant mitigation of the bFGF concentration. In the present data, there was no connection
between the VEGF concentration and the patients’ ages. Women showed significantly higher levels of VEGF. There
was no significant change of VEGF concentration or the VEGF/bFGF ratio during HBO. All scored results varied
within the range of standard values as described in the current literature.
Conclusions: A significant effect of HBO on serum concentrations of bFGF and VEGF was not verified in the
present study. Additional application of exogenous growth factors in conjunction with HBO was not obviously
linked by a coherent cause-and-effect chain as far as wound healing is concerned.
Background
Therapeutic administration of HBO was first mentioned
in 1873 when miners were treated for decompression
sickness [1]. Today, hyperbaric oxygen therapy is an
effective treatment modality in the management of a
variety of disorders, such as severe anaemia, gas
gangrene, arterial gas embolism, carbon monoxide poi-
soning, radiation injuries, necrotizing infections, refrac-
tory wounds and chronic osteomyelitis but also acute
ischemic disorders like acute sensorineural hearing loss
or ischemic stroke [2].
Hyperbaric oxygen therapy involves the intermittent
inhalation of 100% oxygen in chambers pressurized
between 1.5 and 3.0 atmosphere absolute (ATA). An
ATA is defined as the atmospheric pressure at sea level
and is equivalent to 101.3 kilopascals or about 14.7
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increase dissolved oxygen content to above physiologic
levels according to Krogh Erlang mechanism [3]. The
benefit of HBO is based on the premise that raising tis-
sue oxygen levels will enhance wound healing ability.
The ignition for healing processes and angiogenesis is
the lack of oxygen, but a sufficient oxygen supply is the
basis for all proliferation or healing activities.
The positive effects of hyperoxia basically are
- vasoconstriction of arterioles, reduction of oedema
- bactericidal impact on anaerobial microbes and
toxin-deactivation
- mobilisation and activation of leucocytes and
macrophages
- activation of fibroblasts’ collagen release
- activation of osteoclasts and stimulation of
osteogensis
- cover of raised oxygen requirement of the damaged
tissue in spite of impaired blood supply via stimulation
of angiogenesis [4,5].
A final destination of all sorts of repair process is the
re-establishment of a sufficient perfusion and oxygen
supply. The present study focuses on the relevant med-
iators of angiogenesis which are vascular endothelial
growth factor (VEGF) and basic growth factor (bFGF).
In angiogenesis, a number of growth factors (for exam-
ple Angiopoietin-1, Platelet derived growth factor,
Hypoxia inducing factor-1a, EphrinB2, Nitric Oxygen
Synthase) have been found to play significant roles;
VEGF and bFGF are the most extensively investigated
angiogenic factors to date [6,7].
A sas i n g l ep o l y p e p t i d eb F G Fi sp r o d u c e db yav a r i -
ety of cell populations, mainly by activated macro-
phages and thrombocytes. It belongs to one of the 22
members of the FGF family and transmits its signals
via tyrosine kinase receptors [8,9]. Due to its ability to
stimulate the activity of fibroblasts, endothelial cells,
smooth muscle cells and neurons, bFGF is involved in
many physiological and pathophysiological processes
like growth, wound and bone healing, cell differentia-
tion and proliferation, but also tumour progression
and metastasis [10,11]. The key ability of bFGF is to
induce angiogenesis via stimulation of VEGF expres-
sion, the effectiveness of a combined application is
therefore easily explained. It is mitogenic on fibroblasts
and endothelial cells [12].
VEGF is homodimer glycoprotein, its family includes 6
related proteins; VEGF 165 is most common and biolo-
gically active [13]. It is released by many cell populations
as fibroblasts, monocytes, macrophages or lymphocytes
[14]. The corresponding receptors belong to the tyrosine
kinase family. VEGF induces angiogenesis on different
levels: it acts as mitogen especially on endothelial cells,
raises the vessel permeability and dilatation by releasing
NO and has chemotactic impact on other growth pro-
moting cell populations [15].
Under hypoxia an increase of VEGF mRNA could be
shown, and in addition to that the RNA’s half-life was
extended. This effect is translated by the hypoxia sensitive
transcription factor HIF-1. The instantaneous angiogenic
effect of VEGF is the increase in vessel permeability
and mitogenic stimulation of endothelial cells. According
to its potential, VEGF is also involved in pathophysiologi-
cal processes like tumour growth; mainly in hypoxic
tumour regions raised VEGF levels could be scored
[16,17].
The idea of the present study was to characterize and
to quantify the effect of HBO on the expression of the
growth factors bFGF and VEGF and, hence, to explain
the mechanism of its therapeutic use.
Methods
Between May and October 1999, specimens were
obtained from 86 persons: 43 patients and 43 control
subjects (Table 1). In the HBO group, 43 patients trea-
ted for acute hearing loss or tinnitus were enrolled. Dur-
ing 10 days, they received HBO for 90 minutes each day,
the applied pressure was 1.55 bar.
Blood samples of 7.5 ml of peripheral blood were taken
on day 1, 2, 5 and 10 of HBO treatment, after examina-
tion and informed consent of the control persons using
standard serum test tubes, respectively; samples were
stored at 2-5°C, centrifuged (1000/min) after a 60-minute
period of coagulation and stored at -80°C until analysis.
VEGF concentrations were assessed by performing a solid-
phase VEGF Immunoassay (VEGF Quantikine, DVE00, R&D
Systems GmbH, Wiesbaden-Nordenstadt, Germany R&D
Systems). The ELISA was performed according to the manu-
facturer’s protocol; its sensitivity was described as < 25 pg/
ml. The concentration of VEGF was expressed as pg/ml.
VEGF was quantified by using a standard curve made by
human VEGF ranging from 62 pg/ml to 707 pg/ml. The
chromogenic reaction was read at 450 nm.
The bFGF concentrations were assessed by performing
a solid-phase bFGF Immunoassay (FGF basic Quanti-
kine, HSFB50, R&D Systems GmbH, Wiesbaden-Nor-
denstadt, Germany R&D Systems). The ELISA was
performed according to the manufacturer’s protocol; its
sensitivity was described as < 5 pg/ml. The concentra-
tion of bFGF was expressed as pg/ml. The bFGF was
q u a n t i f i e db yu s i n gas t a n d a r dc u r v em a d eb yh u m a n
bFGF ranging from 0 pg/ml to 4.40 pg/ml. The chromo-
genic reaction was read at 490 nm.
Evaluated parameters
The evaluation focused on the most important angio-
genic factors VEGF and bFGF and their serological
values (Table 2) [18,19].
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The results are expressed as mean values +/- standard
deviations (SD) for each group. Normal curve of distri-
bution of results, means and SD were controlled with
the David, Pearson and Stephens test. Data were statisti-
cally analyzed by using the analysis of variance
(ANOVA) and Scheffe test. Differences between groups
were assessed using the Whitney Mann U-test. An error
probability of p < 0.05 was adopted as the statistically
significant level.
Results
bFGF
There was no significant difference in bFGF concentra-
tion between HBO and control group before HBO.
There was no sex- or age dependency according to our
results. In the present study, under HBO a significant
mitigation of the bFGF concentration within standard-
values could be observed (Table 3). Differences between
bFGF concentrations at day 1 and day 10 within the
HBO group reached statistical significance (p = 0.041).
VEGF
There was a significant difference in VEGF concentra-
tion between patients and control group before HBO (p
= 0.015). In our results there was no connection
between the VEGF concentration and the patients’ ages.
Women showed significantly higher levels of VEGF
(279.65 +/- 243.70 pg/ml) compared to male subjects
(193.58 +/- 162.39 pg/ml) (p = 0.026). There was no sig-
nificant change of VEGF concentration under HBO
(Table 4).
VEGF/bFGF ratio
Although a slight increase of the ratio could be docu-
mented, there was no significant variance of the VEGF/
bFGF ratio in the present study (Figure 1).
Discussion
Under HBO therapy a significant reduction of bFGF was
detected. The concentration of VEGF did not change
but was measured significantly higher in female test per-
sons. All collected results were within the range of stan-
dard values according to the current literature.
The influence of the ischemic inner-ear disorder for
which the HBO group was treated could not be fully
excluded as an interfering factor. Yet it seemed highly
implausible because so far only grave diseases have been
reported to affect bFGF and VEGF concentration [20].
There are several explanations for the reduced bFGF
level under HBO. One hypothesis states that there are
simply more bFGF molecules binding on their receptor
and transmitting their signal. These molecules are no
longer detectable for the performed assays.
There might be a higher rate of binding on circulation
proteins in the course of repair processes: these ligand-
receptor complexes are possibly the activating agents
inducing fibroblast proliferation, collagen release, osteo-
and angioneogenesis.
Eventually, a therapy period of ten days was observed.
Possibly, there was a delayed cellular adaptation to the
HBO treatment, where protective cell populations have
to be activated for repair mechanisms to oxygen free-
radical damage. There are hints in literature that effec-
tive cellular responses to HBO cannot be expected
before day seven of treatment [21].
Another consideration is that acute sensoneurinal
hearing loss and tinnitus do not require the induction of
wound healing algorithm to a comparable extend as tis-
sue lesions or chronic infections do. So the restraint
reaction of bFGF and VEGF in our data might be
explained.
Table 1 Patient data
n sex age average SD diagnosis
HBO group 43 22 ♂,2 1♀ 16-62 years 43.3 years 11.4 years 28 acute hearing loss
15 tinnitus
Control group 43 19 ♂,2 4♀ 18-65 years 29.9 years 14.1 years -
Distribution of sex and age in the study and the control group (SD = standard deviation)
Table 2 Characteristics of bFGF and VEGF
gene weight receptor synthesis standard value
pg/ml
bFGF 5p12-
p13
18 kDa tyrosine
kinase
macrophages 2.45
VEGF 6p12-
p21
39-45
kDa
tyrosine
kinase
fibroblasts 224
Characteristics of bFGF and VEGF
Table 3 Serological values of bFGF
bFGF in pg/ml
mean SD
Control group 2.65 3.01
HBO group - day 1 3.25 2.38
day 2 2.80 1.94
day 5 2.55 1.72
day 10 2.12 1.23
Serological values of bFGF in the study and the control group at definite
times
Jung et al. Head & Face Medicine 2010, 6:29
http://www.head-face-med.com/content/6/1/29
Page 3 of 5The observed higher levels of VEGF in females find
their explication in their cycle-dependent hormone
regulation.
As far as VEGF concentration during HBO is con-
cerned our data suggests that the reactive hypoxia was
not enough of a stimulus for increased VEGF release.
Yet in-vivo and in-vitro studies have underlined the fact
that hypoxia is a potent stimulus for VEGF release [22].
In malignantly transformed tissues the highest rates of
VEGF were found in hypoxic, necrotic areas [23].
Application of recombinant human VEGF showed
promising results in animal studies by promoting collat-
eral formation in occluded vessels or proliferation of
endothelial cells in severed arteries [24].
A not yet mentioned field of interest dealing with
VEGF lies in tumour diagnosis and follow-up care.
VEGF might be able to act as an indicator of tumour
neo angiogenesis for elevated VEGF levels are observed
and even correlate with the tumour mass in patients
with malignant melanoma [25].
Some tumour entities as sarcomas are not accompa-
nied by elevated tumour markers like PSA in prostate
cancer [26,27]. As soon as VEGF’s role in tumour
growth, in metastasis and, in particular, tumour neo-
angiogenesis will be furthere l u c i d a t e d ,V E G Fs e r u m
level and its development during the etiopathology
might become valuable prognostic tools [28,29].
Conclusions
Although in the present data a significant effect of HBO on
serum concentrations of bFGF and VEGF was not verified,
many studies revealed that intermittent HBO exposure
plays a direct role in vascular growth; the biochemical pro-
cesses, however, have not been fully understood. Additional
application of exogenous growth factors in conjunction
with HBO was not obviously linked by a coherent cause-
and-effect chain as far as wound healing is concerned.
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